Department of Anesthesiology, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan, Nanjing, 210011, China.
Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, China.
Dig Dis Sci. 2018 Jun;63(6):1633-1640. doi: 10.1007/s10620-018-5034-3. Epub 2018 Mar 29.
Dexmedetomidine as a conscious sedative exhibits both analgesia and respiratory sparing effects.
We evaluated and compared the sedative effect and the safety of a dexmedetomidine-remifentanil (DR) regimen with a midazolam-remifentanil (MR) combination during the endoscopic retrograde cholangio-pancreatography (ERCP) requiring conscious sedation.
One-hundred and ninety-eight patients were randomized and divided into two groups. A bolus of midazolam (0.05 mg kg) was injected intravenously for MR group, and dexmedetomidine (1 μg kg) was pumping for 10 min for DR group. Next, an initial loading dose of 1 μg kg and 0.05-0.2 μg kg min of remifentanil was administered in all patients. Hemodynamic and respiratory changes, Ramsay Sedation Scale, Visual Analogue Scale, endoscopist and patient satisfaction were assessed. Furthermore, adverse events as well as recovery time and discharge time were rated.
Patient satisfaction scores were significantly higher in the DR group compared with MR group. The occurrence of desaturation was statistically higher, and the operation time was longer in the MR group. Although no statistically significant values could be determined between the two groups about amnesia and need of additional drug, the DR group was found to require a significantly reduced amount of extra midazolam. Furthermore, nausea during catheterization of oropharynx was found to be more pronounced in the DR group.
The dexmedetomidine-remifentanil protocol provided a parallel sedative efficacy and improved respiratory sparing effects. The higher patient satisfaction scores potentially offer a more reproducible ERCP quality. Adding dexmedetomidine to remifentanil can be used safely as a conscious sedation method during ERCP.
右美托咪定作为一种镇静剂,具有镇痛和呼吸保护作用。
我们评估和比较了右美托咪定-瑞芬太尼(DR)方案与咪达唑仑-瑞芬太尼(MR)联合方案在需要镇静的内镜逆行胰胆管造影(ERCP)中的镇静效果和安全性。
198 例患者随机分为两组。MR 组静脉注射咪达唑仑(0.05mg/kg),DR 组静脉注射右美托咪定(1μg/kg)10min。然后,所有患者给予初始负荷剂量 1μg/kg和 0.05-0.2μg/kg·min 瑞芬太尼。评估血流动力学和呼吸变化、Ramsay 镇静评分、视觉模拟评分、内镜医师和患者满意度。此外,还评估了不良反应以及恢复时间和出院时间。
DR 组患者满意度评分明显高于 MR 组。MR 组患者出现低氧血症的发生率较高,手术时间较长。虽然两组在遗忘和需要额外药物方面没有统计学差异,但 DR 组需要的额外咪达唑仑明显减少。此外,DR 组在经口咽部置管时恶心的发生率较高。
右美托咪定-瑞芬太尼方案提供了一种平行的镇静效果,并改善了呼吸保护作用。更高的患者满意度评分可能提供了更可重复的 ERCP 质量。在 ERCP 中,瑞芬太尼中加入右美托咪定可以安全使用作为一种镇静方法。